154 related articles for article (PubMed ID: 34431852)
1. Fertility preservation in breast cancer with oral progestin: is it an option? A pilot study.
Oliveira R; Maya BG; Nogueira MBS; Conceição GS; Bianco B; Barbosa CP
Einstein (Sao Paulo); 2021; 19():eAO5859. PubMed ID: 34431852
[TBL] [Abstract][Full Text] [Related]
2. Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study.
Vuong TN; Ho MT; Ha TD; Phung HT; Huynh GB; Humaidan P
Fertil Steril; 2016 Feb; 105(2):356-63. PubMed ID: 26523330
[TBL] [Abstract][Full Text] [Related]
3. The prevention of ovarian hyperstimulation syndrome.
Corbett S; Shmorgun D; Claman P; ;
J Obstet Gynaecol Can; 2014 Nov; 36(11):1024-1033. PubMed ID: 25574681
[TBL] [Abstract][Full Text] [Related]
4. Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies.
Meirow D; Raanani H; Maman E; Paluch-Shimon S; Shapira M; Cohen Y; Kuchuk I; Hourvitz A; Levron J; Mozer-Mendel M; Brengauz M; Biderman H; Manela D; Catane R; Dor J; Orvieto R; Kaufman B
Fertil Steril; 2014 Aug; 102(2):488-495.e3. PubMed ID: 24934489
[TBL] [Abstract][Full Text] [Related]
5. Impact of an oral gonadotropin-releasing hormone antagonist on severe ovarian hyperstimulation syndrome in a patient with breast cancer who received a sustained-release gonadotropin-releasing hormone agonist: A case report.
Hanada T; Kimura F; Kitazawa J; Morimune A; Murakami T
J Obstet Gynaecol Res; 2021 Dec; 47(12):4472-4477. PubMed ID: 34636462
[TBL] [Abstract][Full Text] [Related]
6. Gonadotropin-releasing hormone antagonist versus agonist administration in women undergoing controlled ovarian hyperstimulation: cycle performance and in vitro steroidogenesis of granulosa-lutein cells.
Minaretzis D; Alper MM; Oskowitz SP; Lobel SM; Mortola JF; Pavlou SN
Am J Obstet Gynecol; 1995 May; 172(5):1518-25. PubMed ID: 7755066
[TBL] [Abstract][Full Text] [Related]
7. Progesterone levels in letrozole associated controlled ovarian stimulation for fertility preservation in breast cancer patients.
Goldrat O; Gervy C; Englert Y; Delbaere A; Demeestere I
Hum Reprod; 2015 Sep; 30(9):2184-9. PubMed ID: 26109617
[TBL] [Abstract][Full Text] [Related]
8. Flexible GnRH Antagonist Protocol versus Progestin-primed Ovarian Stimulation (PPOS) Protocol in Patients with Polycystic Ovary Syndrome: Comparison of Clinical Outcomes and Ovarian Response.
Xiao ZN; Peng JL; Yang J; Xu WM
Curr Med Sci; 2019 Jun; 39(3):431-436. PubMed ID: 31209815
[TBL] [Abstract][Full Text] [Related]
9. Gonadotropin-releasing hormone agonist trigger increases the number of oocytes and embryos available for cryopreservation in cancer patients undergoing ovarian stimulation for fertility preservation.
Pereira N; Kelly AG; Stone LD; Witzke JD; Lekovich JP; Elias RT; Schattman GL; Rosenwaks Z
Fertil Steril; 2017 Sep; 108(3):532-538. PubMed ID: 28865552
[TBL] [Abstract][Full Text] [Related]
10. Antral follicle count recovery in women with menses after treatment with and without gonadotropin-releasing hormone agonist use during chemotherapy for breast cancer.
Sinha N; Letourneau JM; Wald K; Xiong P; Imbar T; Li B; Harris E; Mok-Lin E; Cedars MI; Rosen MP
J Assist Reprod Genet; 2018 Oct; 35(10):1861-1868. PubMed ID: 30066303
[TBL] [Abstract][Full Text] [Related]
11. BRCA1/2 gene mutations do not affect the capacity of oocytes from breast cancer candidates for fertility preservation to mature in vitro.
Grynberg M; Dagher Hayeck B; Papanikolaou EG; Sifer C; Sermondade N; Sonigo C
Hum Reprod; 2019 Feb; 34(2):374-379. PubMed ID: 30561604
[TBL] [Abstract][Full Text] [Related]
12. Use of progestins to inhibit spontaneous ovulation during ovarian stimulation: the beginning of a new era?
La Marca A; Capuzzo M
Reprod Biomed Online; 2019 Aug; 39(2):321-331. PubMed ID: 31138494
[TBL] [Abstract][Full Text] [Related]
13. Comparison of euploidy rates of blastocysts in women treated with progestins or GnRH antagonist to prevent the luteinizing hormone surge during ovarian stimulation.
La Marca A; Capuzzo M; Sacchi S; Imbrogno MG; Spinella F; Varricchio MT; Minasi MG; Greco P; Fiorentino F; Greco E
Hum Reprod; 2020 Jun; 35(6):1325-1331. PubMed ID: 32395749
[TBL] [Abstract][Full Text] [Related]
14. The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review.
Rodgers RJ; Reid GD; Koch J; Deans R; Ledger WL; Friedlander M; Gilchrist RB; Walters KA; Abbott JA
Hum Reprod; 2017 May; 32(5):1033-1045. PubMed ID: 28333356
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of fertility preservation in women with endometriosis: comparison of progestin-primed ovarian stimulation versus antagonist protocols.
Mathieu d'Argent E; Ferrier C; Zacharopoulou C; Ahdad-Yata N; Boudy AS; Cantalloube A; Levy R; Antoine JM; Daraï E; Bendifallah S
J Ovarian Res; 2020 Feb; 13(1):18. PubMed ID: 32054493
[TBL] [Abstract][Full Text] [Related]
16. Response to ovarian stimulation is not impacted by a breast cancer diagnosis.
Quinn MM; Cakmak H; Letourneau JM; Cedars MI; Rosen MP
Hum Reprod; 2017 Mar; 32(3):568-574. PubMed ID: 28122888
[TBL] [Abstract][Full Text] [Related]
17. Medroxyprogesterone acetate is a useful alternative to a gonadotropin-releasing hormone antagonist in oocyte donation: a randomized, controlled trial.
Giles J; Alama P; Gamiz P; Vidal C; Badia P; Pellicer A; Bosch E
Fertil Steril; 2021 Aug; 116(2):404-412. PubMed ID: 33814126
[TBL] [Abstract][Full Text] [Related]
18. Predicting successful induction of oocyte maturation after gonadotropin-releasing hormone agonist (GnRHa) trigger.
Kummer NE; Feinn RS; Griffin DW; Nulsen JC; Benadiva CA; Engmann LL
Hum Reprod; 2013 Jan; 28(1):152-9. PubMed ID: 23077235
[TBL] [Abstract][Full Text] [Related]
19. Antral follicle responsiveness to FSH, assessed by the follicular output rate (FORT), is altered in Hodgkin's lymphoma when compared with breast cancer candidates for fertility preservation.
Sonigo C; Comtet M; Duros S; Sifer C; Sermondade N; Grynberg M
J Assist Reprod Genet; 2018 Jan; 35(1):91-97. PubMed ID: 28986734
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of controlled ovarian stimulation using GnRH antagonist protocols for emergency fertility preservation in young women with breast cancer-a prospective nationwide Swedish multicenter study.
Marklund A; Eloranta S; Wikander I; Kitlinski ML; Lood M; Nedstrand E; Thurin-Kjellberg A; Zhang P; Bergh J; Rodriguez-Wallberg KA
Hum Reprod; 2020 Apr; 35(4):929-938. PubMed ID: 32313940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
